The Role of the Coordinating Centers for Biometric Research in West African Biomedical Research

Cavan Reilly, Division of Biostatistics
The CCBR

- Group of about 50 biostatisticians, data managers and protocol managers
- Started out conducting cardiovascular and pulmonary health research in the 1970’s
- Branched out to HIV/AIDS research in the 1980’s
- Moved into the study of other infectious diseases about 10 years ago (H1N1 pandemic of 2009)
HIV/AIDS Research

  - CD4 guided, antiretroviral drug “holidays” are associated with increased morbidity and mortality

  - Antiretroviral treatment should be initiated immediately upon diagnosis
Ebola Research

• August 2014: WHO declares the West African outbreak a public health emergency
  - The Liberian Minister of Health reaches out to the US director of Health and Human Services
• February 2, 2015: First patient randomized in a phase 2/3, double-blind controlled vaccine trial (n=27,000)
  - Resource limitations: physical randomization, paper case report forms, unreliable electricity and internet
  - Research during an epidemic: impossible?
Redemption Hospital

Global Health Day, 2018
Ebola Research

• The trial, called PREVAIL I, was stopped early for futility for the primary efficacy endpoint
  - We did demonstrate safety and immunogenicity (N Engl J Med 2017; 377:1438-1447)
• We also implemented a treatment trial of Zmapp, but that too was stopped prior to its enrolment goal due to futility (N Engl J Med 2016; 375:1448-1456)
• A cohort study of survivors, PREVAIL III, was initiated in June 2015
Ebola Research

- PREVAIL III distinguishing features:
  - Largest cohort of Ebola survivors ever studied (over 1100 survivors)
  - Matched group of contacts during infection (over 2700 contacts, which serve as controls)
  - Serologic data available for all participants
    - Allows us to see who mounted an immune response
  - Follow-up visits every 6 months for 5 years
  - Extensive laboratory data and physical exams
  - Numerous sub-studies (e.g. ophthalmological, neurological and a birth cohort)
Ebola Research—still enrolling

- PREVAIL IV: a double-blind, randomized controlled trial of an antiviral compound with the potential to clear Ebola RNA from the urogenital tract of male survivors
- PREVAIL V/PREVAC: a double-blind, randomized controlled vaccine trial (in Liberia, Sierra Leone, Guinea and Mali)
- PREVAIL VI: a genome-wide association study of the impact of host genetic factors on the clinical course of Ebola infection

Global Health Day, 2018
Thanks to study participants and hundreds of study staff in Liberia, at the NIH and at the CCBR.